미국의 멸균 서비스 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the united states sterilization services market size is projected to expand from USD 1.77 billion in 2025 and USD 1.88 billion in 2026 to USD 2.55 billion by 2031, registering a CAGR of 6.25% between 2026 to 2031.

This report is Segmented by Method (EtO Sterilization, Gamma Irradiation, E-Beam, and More), Mode of Delivery (Off-Site, On-site/In-house-as-a-Service), Service Type (Contract Sterilization, Validation & Testing, and More), and End User (Medical Device Manufacturers, Pharma & Biopharma, Hospitals & ASCs, and More). The Market Forecasts are Provided in Terms of Value (USD).

United States Sterilization Services Market Trends and Insights

Rising HAI Burden and Procedure Throughput

Healthcare-associated infections continue to keep sterilization performance under close clinical scrutiny, and the CDC's 2023 national and state report showed that device-related and procedure-related infection control remains a material issue for acute care settings. In the United States sterilization services market, that pressure matters because more procedures are moving through ambulatory settings that want hospital-grade sterility assurance without the full footprint of advanced in-house infrastructure. Higher-acuity case migration into ambulatory surgery centers increases the need for validated processing, packaging integrity, and documented release controls. That shift supports more off-site contract demand because many centers have limited space for multi-modal equipment and limited tolerance for process failure. The United States sterilization services market therefore benefits when procedure growth and infection prevention standards rise together, since both push customers toward more formal sterilization partnerships.

Outsourcing by Device and Pharma Manufacturers

The market is seeing stronger outsourcing momentum because QMSR raises the cost of running compliant internal sterilization operations and makes vendor oversight more visible during inspections. RAPS reported that outsourcing and purchasing controls ranked as the second-most-cited QMSR observation in more than 100 completed inspections as of May 2026, which shows how closely the FDA is reviewing supplier management. ISO 13485:2016 Clause 4.1.5 now carries more weight in practice because outsourced processes must be controlled in proportion to risk, and sterilization is one of the clearest examples of that rule. Large contract providers gain an advantage under this framework because they can offer documented quality systems, validation records, and audit-ready traceability as part of the service. That is why the United States sterilization services market is shifting toward bigger, multi-modal platforms for long-term outsourced agreements.

EtO Emissions and Compliance Volatility

EtO remains indispensable for many heat-sensitive products, but the United States sterilization services market faces uncertainty because the regulatory framework around emissions has changed quickly and remains contested. The EPA's 2024 final rule projected USD 313 million in capital investment and USD 74 million in annualized compliance costs across 89 commercial EtO facilities, which materially changed the economics of standalone gas operations. The March 2026 reconsideration proposal then reopened core issues including risk-based standards, enclosure requirements, and continuous monitoring, which shortened planning horizons for operators and customers alike. STERIS stated in January 2025 that an Illinois EtO trial had concluded, which highlights that legal exposure has become part of the operating environment for major participants as well. In the United States sterilization services market, this volatility pushes customers toward suppliers that can offer EtO only where needed and shift the rest of the load into radiation or other lower-temperature options.

Other drivers and restraints analyzed in the detailed report include:

1. Single-Use and Minimally Invasive Device Expansion
2. X-Ray Capacity Build-Outs Reducing EtO and Cobalt-60 Bottlenecks
3. High Capex for Compliant Multi-Modal Capacity

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

EtO sterilization accounted for 45.31% of the United States sterilization services market share by method in 2025, and that position still reflects its fit for heat-sensitive devices and complex assemblies. The EPA stated that EtO sterilizes 50% of all medical devices used in the country each year, or more than 20 billion units, which explains why the method remains hard to displace even under tighter regulation. Gamma irradiation held the second-largest position, supported by established customer validation pathways and cobalt-60-linked supply capacity. Sotera Health reported 25.8% constant-currency growth in Nordion cobalt-60 revenue in Q1 2026, which showed continued demand for radiation inputs tied to the broader sterilization ecosystem.

X-ray irradiation is the fastest-growing method in the United States sterilization services market, with forecast growth of 9.38% through 2031. Sterigenics and STERIS both expanded commercial X-ray capacity, which signals that accelerator-based radiation is moving into a more mainstream role for contract services. BGS US also added E-Beam capacity in Pennsylvania in 2025, which widened the radiation choice set for manufacturers in the Northeast and mid-Atlantic. VHP, NO2, E-Beam, and dry-heat remain smaller niches, but their role rises when customers need low-temperature processing, fast turnaround, or better compatibility with sensitive materials.

Off-site service-center sterilization held 66.24% of United States sterilization services market share by delivery mode in 2025, supported by the high cost of maintaining compliant multi-modal infrastructure inside each manufacturing site. The model remains attractive because it gives customers access to validated processes, trained operators, and established release documentation without full facility ownership. It also fits the long-duration service agreements that stabilize throughput for large contract sterilizers. In practice, this keeps the off-site model central to the United States sterilization services market even as customers ask for more redundancy and closer proximity to production lines.

On-site or in-house-as-a-service is the fastest-growing delivery model, with the United States sterilization services market size for this segment projected to grow at an 8.52% CAGR through 2031. Under this approach, the service provider installs, qualifies, and operates equipment at the customer site while maintaining the quality trail expected for outsourced processes. QMSR supports that shift because it places stronger emphasis on documented control over outsourced activities and clearer accountability across supplier relationships. That makes the model especially attractive for high-volume pharmaceutical programs and device lines that need more supply chain flexibility without taking on full regulatory responsibility for the sterilization unit.

List of Companies Covered in this Report:

1. Advanced Sterilization Products (ASP)
2. American Sterilizer Services
3. BGS US LLC
4. Cosmed Group
5. Eagle Medical, Inc.
6. E-BEAM Services, Inc.
7. Infinity Laboratories / Eurofins Infinity Laboratory Group
8. IsoTex, Inc.
9. Life Science Outsourcing, Inc.
10. Midwest Sterilization Corporation
11. Noxilizer
12. Prince Sterilization Services
13. Quantum EBX
14. Remington Medical
15. SGS
16. Sotera Health
17. STERIS
18. Steri-Tek
19. VPT Rad, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising HAI Burden and Procedure Throughput
  • 4.2.2 Outsourcing by Device and Pharma Manufacturers
  • 4.2.3 FDA QMSR and ISO 13485 Alignment
  • 4.2.4 Single-Use and Minimally Invasive Device Expansion
  • 4.2.5 AI-Enabled Chain-of-Custody and Cycle-Tracking
  • 4.2.6 X-Ray Capacity Build-Outs Reducing EtO and Cobalt-60 Bottlenecks
• 4.3 Market Restraints
  • 4.3.1 EtO Emissions and Compliance Volatility
  • 4.3.2 High Capex for Compliant Multi-Modal Capacity
  • 4.3.3 Sterility-Assurance Talent Shortage
  • 4.3.4 Material-Compatibility Failures When Shifting Modalities
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Method
  • 5.1.1 Ethylene Oxide (EtO) Sterilization
  • 5.1.2 Gamma Irradiation
  • 5.1.3 Electron-Beam (E-beam) Irradiation
  • 5.1.4 X-ray Irradiation
  • 5.1.5 Steam (Moist-Heat) Sterilization
  • 5.1.6 Dry-Heat Sterilization
  • 5.1.7 Vaporized Hydrogen Peroxide / Gas Plasma Sterilization
  • 5.1.8 Nitrogen Dioxide Sterilization
• 5.2 By Mode of Delivery
  • 5.2.1 Off-site (Service-Center) Sterilization
  • 5.2.2 On-site / In-house-as-a-Service Sterilization
• 5.3 By Service Type
  • 5.3.1 Contract Sterilization Services
  • 5.3.2 Sterilization Validation & Testing Services
  • 5.3.3 Process Development, Advisory & Optimization Services
• 5.4 By End User
  • 5.4.1 Medical Device Manufacturers
  • 5.4.2 Pharmaceutical & Biopharmaceutical Manufacturers
  • 5.4.3 Hospitals & Ambulatory Surgery Centers
  • 5.4.4 Clinical Laboratories & Research Organizations
  • 5.4.5 Other End Users

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Advanced Sterilization Products (ASP)
  • 6.3.2 American Sterilizer Services
  • 6.3.3 BGS US LLC
  • 6.3.4 Cosmed Group
  • 6.3.5 Eagle Medical, Inc.
  • 6.3.6 E-BEAM Services, Inc.
  • 6.3.7 Infinity Laboratories / Eurofins Infinity Laboratory Group
  • 6.3.8 IsoTex, Inc.
  • 6.3.9 Life Science Outsourcing, Inc.
  • 6.3.10 Midwest Sterilization Corporation
  • 6.3.11 Noxilizer, Inc.
  • 6.3.12 Prince Sterilization Services, LLC
  • 6.3.13 Quantum EBX
  • 6.3.14 Remington Medical
  • 6.3.15 SGS SA
  • 6.3.16 Sotera Health
  • 6.3.17 STERIS plc
  • 6.3.18 Steri-Tek
  • 6.3.19 VPT Rad, Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment